Literature DB >> 33392716

To go where no one has gone before: the necessity of radiobiology studies for exploration beyond the limits of the "Holy Gray" in radionuclide therapy.

Frederik A Verburg1, Julie Nonnekens2,3,4, Mark W Konijnenberg2,5, Marion de Jong2.   

Abstract

Mesh：

Substances：

Year:  2021        PMID： 33392716     DOI： 10.1007/s00259-020-05147-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  3 in total

1.  [Dosimetry of radioactive isotopes; biological observations and practical applications].

Authors:  L D MARINELLI; E H QUIMBY; G HINE
Journal:  Strahlentherapie       Date:  1950

2.  Age and gender predict the outcome of treatment for Graves' hyperthyroidism.

Authors:  A Allahabadia; J Daykin; R L Holder; M C Sheppard; S C Gough; J A Franklyn
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

3.  Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.

Authors:  George Sgouros; Katherine S Kolbert; Arif Sheikh; Keith S Pentlow; Edward F Mun; Axel Barth; Richard J Robbins; Steven M Larson
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057
  3 in total
  2 in total

1.  EANM position paper on the role of radiobiology in nuclear medicine.

Authors:  An Aerts; Uta Eberlein; Sören Holm; Roland Hustinx; Mark Konijnenberg; Lidia Strigari; Fijs W B van Leeuwen; Gerhard Glatting; Michael Lassmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-29       Impact factor: 9.236

Review 2.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.